ReviewCardiology research2026
Definition of Polypharmacy in Atrial Fibrillation and Atrial Flutter: A Scoping Review.
Review in Cardiology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polypharmacy lacks a consistent definition in the literature and studies use varying numeric thresholds, ranging from the use of four to as many as 15 medications with the most frequent cutoff being five or more medications. It is highly prevalent and particularly relevant in patients with atrial fibrillation (AF) and atrial flutter (AFL) who have multiple comorbidities and often require multi-agent therapy. As a result, these patients face increased risk of bleeding, falls, drug-drug interactions, adverse drug-related events, and medication non-adherence. This scoping review aims to identify how polypharmacy is defined in AF and AFL, to examine the clinical consequences of these definitions, and summarize considerations to prevent polypharmacy. A comprehensive literature search was completed across five databases to identify articles that address and define polypharmacy in AF and AFL. A protocol was prospectively registered on PROSPERO (CRD420251135482) before data extraction began. Included articles defined polypharmacy in adult patients with a diagnosis of AF or AFL. Of the 109 articles identified, 96% (n = 105) discussed AF only, 4% (n = 4) discussed AF and AFL together without differentiation, and none focused solely on AFL. Most articles (96%, n = 105) used a quantitative definition, while 4% (n = 4) used a qualitative definition. The most common definition of polypharmacy, reported in 51% (n = 56) of articles, was the use of five or more medications. This definition is not clinically meaningful as most patients with AF or AFL are already on five or more medications. There is ongoing debate on the definition of polypharmacy in this population. If a numeric cutoff is utilized, we propose increasing it to 10 or more medications as has been suggested in other cardiovascular conditions such as heart failure. More importantly, regardless of how we define polypharmacy in AF or AFL, it is crucial that providers continually assess each medication to ensure that the benefits outweigh the risks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.